A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Abstract Background Fragile X syndrome (FXS) is associated with dysregulated endocannabinoid signaling and may therefore respond to cannabidiol therapy. Design CONNECT-FX was a double-blind, randomized phase 3 trial assessing efficacy and safety of ZYN002, transdermal cannabidiol gel, for the treatm...

Full description

Bibliographic Details
Main Authors: Elizabeth Berry-Kravis, Randi Hagerman, Dejan Budimirovic, Craig Erickson, Helen Heussler, Nicole Tartaglia, Jonathan Cohen, Flora Tassone, Thomas Dobbins, Elizabeth Merikle, Terri Sebree, Nancy Tich, Joseph M. Palumbo, Stephen O’Quinn
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Journal of Neurodevelopmental Disorders
Subjects:
Fragile X syndrome
Clinical trial
Endocannabinoid system
Cannabidiol
Online Access:https://doi.org/10.1186/s11689-022-09466-6

Internet

https://doi.org/10.1186/s11689-022-09466-6

Similar Items